FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF LOMUSTINE AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA

被引：0

作者：

Lazaridis, L. ^{[1
,2
]}

Schmidt, T. ^{[1
,2
]}

Agkatsev, S. ^{[1
,2
]}

Blau, T. ^{[3
]}

Spille, D. ^{[4
]}

Heider, S. ^{[5
]}

Schulz, T. ^{[6
]}

Bumes, E. ^{[7
]}

Oster, C. ^{[1
,2
]}

Feldheim, J. ^{[1
,2
]}

Stummer, W.

Kessler, A. ^{[6
]}

Seidel, C. ^{[5
]}

Hau, P. ^{[7
]}

Sure, U. ^{[8
]}

Keyvani, K. ^{[3
]}

Herrlinger, U. ^{[9
]}

Kleinschnitz, C. ^{[1
,2
]}

Stuschke, M. ^{[10
]}

Herrmann, K. ^{[11
]}

Deuschl, C. ^{[12
]}

Hattingen, E. ^{[13
]}

Scheffler, B. ^{[14
]}

Kebir, S. ^{[1
,2
]}

Glas, M. ^{[1
,2
]}

机构：

[1] Univ Med Essen, Div Clin Neurooncol, Ctr Translat Neuro & Behav Sci C TN, Essen, Germany

[2] Univ Med Essen, Dept Neurol, Essen, Germany

[3] Univ Med Essen, Inst Neuropathol, Essen, Germany

[4] Univ Hosp Munster, Dept Neurosurg, Munster, Germany

[5] Univ Hosp Leipzig, Dept Radiotherapy & Radiat Oncol, Leipzig, Germany

[6] Univ Hosp Wurzburg, Dept Neurosurg, Wurzburg, Germany

[7] Univ Hosp Regensburg, Dept Neurol & Wilhelm Sander NeuroOncol Unit, Regensburg, Germany

[8] Univ Med Essen, Dept Neurosurg & Spine Surg, Essen, Germany

[9] Univ Hosp Bonn, Div Clin Neurooncol, Dept Neurol & Ctr Integrated Oncol, Bonn, Germany

[10] Univ Med Essen, Dept Radiotherapy, Essen, Germany

[11] Univ Med Essen, Dept Nucl Med, Essen, Germany

[12] Univ Med Essen, Inst Diagnost & Intervent Radiol & Neurora, Essen, Germany

[13] Univ Hosp Frankfurt, Inst Neuroradiol, Frankfurt, Germany

[14] Univ Med Essen, West German Canc Ctr WTZ, DKFZ Div Translat Neurooncol, DKTK Partner Site, Essen, Germany

来源：

NEURO-ONCOLOGY | 2022年 / 24卷

关键词：

D O I：

10.1093/neuonc/noac174.204

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P11.15.B

引用

页数：2

共 50 条

[1] FIRST MULTICENTRIC REAL-LIFE EXPERIENCE WITH THE COMBINATION OF CCNU AND TEMOZOLOMIDE IN NEWLY DIAGNOSED MGMT PROMOTER METHYLATED IDH WILDTYPE GLIOBLASTOMA
Lazaridis, Lazaros
Bumes, Elisabeth
Spille, Dorothee Cacilia
Schulz, Tim
Heider, Sina
Agkatsev, Sarina
Schmidt, Teresa
Blau, Tobias
Oster, Christoph
Feldheim, Jonas
Stummer, Walter
Kessler, Almuth Friederike
Seidel, Clemens
Grauer, Oliver
Hau, Peter
Sure, Ulrich
Keyvani, Kathy
Herrlinger, Ulrich
Kleinschnitz, Christoph
Stuschke, Martin
Herrmann, Ken
Deuschl, Cornelius
Breuer, Stella
Hattingen, Elke
Scheffler, Bjoern
Kebir, Sied
Glas, Martin
NEURO-ONCOLOGY, 2022, 24 : 74 - 74
[2] First multicentric real-life experience with the combination of CCNU and temozolomide in newly diagnosed MGMT promoter methylated IDH wildtype glioblastoma
Lazaridis, Lazaros
Bumes, Elisabeth
Spille, Dorothee Caecilia
Schulz, Tim
Heider, Sina
Agkatsev, Sarina
Schmidt, Teresa
Blau, Tobias
Oster, Christoph
Feldheim, Jonas
Stummer, Walter
Kessler, Almuth Friederike
Seidel, Clemens
Grauer, Oliver
Hau, Peter
Sure, Ulrich
Keyvani, Kathy
Herrlinger, Ulrich
Kleinschnitz, Christoph
Stuschke, Martin
Herrmann, Ken
Deuschl, Cornelius
Breuer, Stella
Hattingen, Elke
Scheffler, Bjoern
Kebir, Sied
Glas, Martin
NEURO-ONCOLOGY ADVANCES, 2022, 4 (01)
[3] Combination Therapy of Lomustine and Temozolomide in Patients with newly diagnosed Glioblastoma with methylated MGMT Promotor
Lenzen, Julia
Feldmann, H. J.
ONKOLOGE, 2019, 25 (12): : 1118 - 1120
[4] Lomustine and temozolomide for newly diagnosed glioblastoma with methylated MGMT promoter: Lessons from the CeTeG/NOA-09 trial
Tremont-Lukats, Ivo W.
Teh, Bin S.
TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S589 - S591
[5] TEMPORAL MUSCLE THICKNESS AS A PROGNOSTIC MARKER IN A REAL-LIFE COHORT OF NEWLY DIAGNOSED MGMT PROMOTER METHYLATED GLIOBLASTOMA PATIENTS: A MULTICENTRIC IMAGING ANALYSIS
Lazaridis, Lazaros
Moenninghoff, Christoph
Bumes, Elisabeth
Spille, Dorothee Caecilia
Muether, Michael
Schulz, Tim
Heider, Sina
Agkatsev, Sarina
Schmidt, Teresa
Blau, Tobias
Oster, Christoph
Stummer, Walter
Kessler, Almuth Friederike
Seidel, Clemens
Grauer, Oliver
Hau, Peter
Sure, Ulrich
Keyvani, Kathy
Herrlinger, Ulrich
Kleinschnitz, Christoph
Stuschke, Martin
Herrmann, Ken
Deuschl, Cornelius
Scheffler, Bjoern
Kebir, Sied
Glas, Martin
NEURO-ONCOLOGY, 2023, 25
[6] TEMPORAL MUSCLE THICKNESS AS A PROGNOSTIC MARKER IN A REAL-LIFE COHORT OF NEWLY DIAGNOSED MGMT PROMOTER METHYLATED GLIOBLASTOMA PATIENTS: A MULTICENTRIC IMAGING ANALYSIS
Lazaridis, L.
Moenninghoff, C.
Schmidt, T.
Agkatsev, S.
Blau, T.
Spille, D.
Heider, S.
Schulz, T.
Bumes, E.
Oster, C.
Stummer, W.
Kessler, A.
Seidel, C.
Hau, P.
Sure, U.
Keyvani, K.
Herrlinger, U.
Grauer, O.
Kleinschnitz, C.
Stuschke, M.
Herrmann, K.
Deuschl, C.
Scheffler, B.
Kebir, S.
Glas, M.
NEURO-ONCOLOGY, 2023, 25
[7] Lomustine–temozolomide combination efficacious in newly diagnosed glioblastoma
David Killock
Nature Reviews Clinical Oncology, 2019, 16 : 273 - 273
[8] Lomustine and Temozolomide in Combination with Radiotherapy New First-Line Treatment Option for Patients with MGMT Promoter methylated Glioblastoma
Seidel, Clemens
Kortmann, Rolf-Dieter
STRAHLENTHERAPIE UND ONKOLOGIE, 2019, 195 (09) : 855 - 856
[9] Lomustine-temozolomide combination efficacious in newly diagnosed glioblastoma
Killock, David
NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (05) : 273 - 273
[10] Topographical Mapping of 436 Newly Diagnosed IDH Wildtype Glioblastoma With vs. Without MGMT Promoter Methylation
Incekara, Fatih
van der Voort, Sebastian R.
Dubbink, Hendrikus J.
Atmodimedjo, Peggy N.
Tewarie, Rishi Nandoe
Lycklama, Geert
Vincent, Arnaud J. P. E.
Kros, Johan M.
Klein, Stefan
van den Bent, Martin
Smits, Marion
FRONTIERS IN ONCOLOGY, 2020, 10

← 1 2 3 4 5 →